Cymbalta for depression, anxiety, neuropathic pain, and fibromyalgia

Cymbalta is a serotonin and norepinephrine reuptake inhibitor (SNRI) medication available as delayed-release capsules. It is approved for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia in adults. Cymbalta helps manage these conditions by affecting brain chemicals involved in mood and pain regulation.

Cymbalta is used in adults for:

• Major depressive disorder (MDD): Treating episodes of depression characterized by persistent depressed mood and related symptoms that interfere with daily functioning.
• Generalized anxiety disorder (GAD): Managing excessive anxiety and worry present for at least 6 months along with associated symptoms like restlessness, irritability, and muscle tension.
• Diabetic peripheral neuropathic pain (DPNP): Treating nerve pain caused by diabetes.
• Fibromyalgia (FM): Managing chronic widespread muscle pain and tenderness.

duloxetine hydrochloride

Cymbalta works by inhibiting the reuptake of two neurotransmitters, serotonin and norepinephrine, in the brain. This increases their levels and activity, which helps improve mood and relieve pain sensations. The balanced action on both serotonin and norepinephrine pathways contributes to its effects in depression, anxiety, and neuropathic pain.

Administration: Capsules should be swallowed whole without chewing or opening, and can be taken with or without food.

Initial and maintenance doses by condition in adults:

• Major depressive disorder: Start 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or 30 mg twice daily). Some patients may start at 30 mg once daily for 1 week for adjustment. Maintenance dose is 60 mg once daily. Maximum studied dose was 120 mg/day, but doses above 60 mg/day do not show additional benefit.
• Generalized anxiety disorder: Start at 60 mg once daily; some patients may start at 30 mg once daily for 1 week before increasing to 60 mg. Maintenance dose 60-120 mg once daily; increases above 60 mg should be by 30 mg increments. No additional benefit above 60 mg/day confirmed.
• Diabetic peripheral neuropathic pain: Recommended dose is 60 mg once daily. No benefit from higher doses; better tolerability at 60 mg or lower. For patients with renal impairment, start at a lower dose and titrate gradually.
• Fibromyalgia: Begin with 30 mg once daily for 1 week, then increase to 60 mg once daily. Some patients may respond to 30 mg alone. No benefit beyond 60 mg/day, and adverse reactions increase at higher doses.

Special populations: Not recommended for patients with hepatic insufficiency or severe renal impairment (creatinine clearance <30 mL/min). No dose adjustment required for elderly but increase dose with caution. Use in pregnancy only if benefits justify risks. Nursing is not recommended due to unknown infant safety.

Discontinuation: Gradual dose reduction is recommended to avoid withdrawal symptoms.

MAOI use: At least 14 days should pass after stopping an MAOI before starting Cymbalta, and wait at least 5 days after stopping Cymbalta before starting an MAOI.

• Concurrent use or recent use (within 14 days) of MAOIs.
• Use in patients with uncontrolled narrow-angle glaucoma due to risk of increased eye pressure (mydriasis).

Suicidality: Antidepressants like Cymbalta may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Close monitoring is necessary, especially when starting treatment or changing the dose. Cymbalta is not approved for patients under 18 years.

Hepatotoxicity: Cases of liver failure, sometimes fatal, have been reported. Discontinue if signs of liver injury such as jaundice occur. Avoid in patients with significant alcohol use or chronic liver disease.

Serotonin syndrome: Risk when used with other serotonergic drugs or MAOIs; symptoms can include high fever, agitation, rigidity, and confusion.

Orthostatic hypotension and syncope: Cases have been reported; monitor patients at risk.

Other warnings: Use cautiously in elderly patients; avoid in uncontrolled narrow-angle glaucoma due to increased risk of eye pressure; monitor closely for worsening psychiatric symptoms.

Common side effects: May include nausea, dry mouth, fatigue, dizziness, constipation, and decreased appetite.

Serious reactions: Liver damage signs, serotonin syndrome, suicidal thoughts or behavior, orthostatic hypotension, and severe allergic reactions have been reported and require immediate medical attention.

Contraindicated with monoamine oxidase inhibitors (MAOIs): Risk of serious, potentially fatal drug interactions including serotonin syndrome and neuroleptic malignant syndrome-like reactions.

Concomitant use with other serotonergic agents may also increase risk of serotonin syndrome.

Pregnancy: No adequate, well-controlled studies in pregnant women. Use only if potential benefit justifies potential fetal risk.

Lactation: Safety in nursing infants is unknown. Nursing while taking Cymbalta is not recommended.

Overdose symptoms and management details are not specified in the supplied evidence.

No specific storage information provided in the label.